UK markets closed

MorphoSys AG (MOR.DE)

XETRA - XETRA Delayed price. Currency in EUR
Add to watchlist
21.06+0.25 (+1.20%)
At close: 05:35PM CEST
Full screen
Previous close20.81
Open21.61
Bid20.70 x 1500
Ask20.74 x 8800
Day's range20.37 - 21.70
52-week range16.08 - 43.29
Volume199,476
Avg. volume197,599
Market cap719.271M
Beta (5Y monthly)0.97
PE ratio (TTM)N/A
EPS (TTM)-17.65
Earnings date16 Nov 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est34.58
  • EQS Group

    MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCL

    EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCL 28.09.2022 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media Release BOSTON, Mass., USA, September 28, 2022 MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R D

  • EQS Group

    MorphoSys appoints Tim Demuth as new Chief Research and Development Officer, following the retirement of Malte Peters

    DGAP-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys appoints Tim Demuth as new Chief Research and Development Officer, following the retirement of Malte Peters 31.08.2022 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, August 31, 2022 MorphoSys appoints Tim Demuth as new Chief Research and Development Officer, following the retirement of Malte PetersTim Demuth, M.D., Ph.D., has more than 20 years of broad leade

  • Motley Fool

    MorphoSys AG (MOR) Q2 2022 Earnings Call Transcript

    At this time, I would like to turn the conference over to Julia Neugebauer. My name is Julia Neugebauer, head of investor relations at MorphoSys, and it is my pleasure to welcome you to our half year 2022 financial results conference call. With me on the call today are Jean-Paul Kress, chief executive officer; Sung Lee, chief financial officer; Malte Peters, chief research and development officer; and Joe Horvat, U.S. general manager.